RETRACTED ARTICLE: The association of Crk-like adapter protein with poor prognosis in glioma patients

• Published in: Tumor biology 2014, Vol.35 (6), p.5695-5700
• Main Authors: Yao, Chengjun, Lv, Shunzeng, Han, Mingzhi, Zhang, Jie, Zhang, Ya, Zhang, Li, Yi, Ruiyang, Zhuang, Dongxiao, Wu, Jinsong
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Cancer Research; Research Article
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1007/s13277-014-1754-y

Glioma is the most common of brain tumors that greatly affects patient survival. In our precious study, Crk-like adapter protein (CrkL) was identified as a key regulator in glioblastoma development [ 1 ]. Here, we aimed to investigate the correlation of CrkL with patient prognosis as well as pathological indicators. Immunohistochemistry was available to evaluate CrkL expression in 49 gliomas of distinct malignancy grade, and positive stained sites were analyzed. CrkL protein was detected in cell lines by Western blot as well. We observed CrkL protein stained in 59.2 % (29 out of 49) of all glioma tissues, including 41.4 % of low-grade (I + II) gliomas, and 85.0 % of high-grade (III + IV) gliomas. Of four grades, grade IV exhibited the highest CrkL level. CrkL protein was also identified in cell lines NHA, U87, U251, T98G, and A172 by Western blot. On the other hand, CrkL expression was significantly associated with the patient’s age and WHO grade, and patients with high CrkL expression had a significantly shorter median survival time (17 months) than those (median survival time 52 months) with low CrkL expression ( p